Ad
Supported by
Two senior fitness officials gave the impression to a Senate panel the day after AstraZeneca announced the suspension of a vaccine test. Britain will ban maximum meetings of more than six other people from Monday.
Maintenance
On September 30, New York’s restaurants can reopen indoor restaurants to 25% of their capacity, said the governor, a major step in the city’s recovery.
transliteration
I cannot say enough that resolutions on how this vaccine will be evaluated and evaluated will be based on science. And I know that I speak on behalf of my colleagues in government, and surely of the clinical network in general, that possibly this is the only basis on which this resolution is made. Otherwise, we wouldn’t be expecting the public to accept it as true with us. This will therefore be the only measure. Will it take place on a certain date? I probably can’t tell you now either because I don’t know what will happen in the next few months. I am cautiously certain that by the end of 2020 at least one of those vaccines will have been released and proven to be safe and effective. But even that is a guess, and surely waiting for whether it will take place in a specific week before or after a specific date in early November is far beyond anything any scientist at this point can tell you, and be sure. they know what they know. Let’s say. So yes, science and science alone will be the way this resolution will be made. Otherwise you might not get any part.
Dr. Francis Collins, director of the National Institutes of Health, challenged President Trump’s suggestion Wednesday that a coronavirus vaccine would be obtained on Election Day, as he continually sought to reassure senators and the public that a vaccine would not be made. accessible to the public unless it is and effective.
“Certainly expecting this to occur a specific week before or after a specific date in early November is far beyond what any scientist at this time can tell you and be sure you know what you are saying,” said Dr. Collins. Senate panel at a hearing on the effort to locate a vaccine.
Wednesday’s hearing before the Senate Committee on Health, Education, Labor, and Pensions came amid growing fears about whether others would hesitate to take a coronavirus vaccine and whether Trump would politically pressure his administration to temporarily approve one to give it. a seasoning in his candidacy for re-election opposed to former Vice President Joseph R. Biden Jr.
At a briefing Wednesday, White House press secretary Kayleigh McEnany rejected criticism.
“Our moment is about the elections,” he said. “It’s about saving lives. “
On Tuesday, an organization of pharmaceutical corporations participating in the vaccine progression race vowed not to launch any vaccine that does not meet rigorous criteria for efficacy and safety. Hours later, a leading vaccine developer, AstraZeneca, announced that it had suspended a large-scale clinical trial of a vaccine candidate after a patient experienced what could be a serious adverse reaction. Dr. Collins pointed to this progression as “a real-life example of how even one case of unforeseen illness from a single person is sufficient to conduct a clinical trial in countries,” and evidence that “we cannot compromise on safety. “
Democrats on the panel asked Dr. Collins and Surgeon General Jerome Adams about the effect of Trump’s false claims about the vaccine and whether they would erode confidence in the progression process. However, Dr. Collins objected, as Senator Elizabeth Warren, a Democrat from Massachusetts, asked him directly whether Trump’s incorrect information would deter other people from taking the vaccine and hamper efforts to distribute it.
“I’m not sure I know the answer to this question,” said Dr. Collins. When Ms Warren pressed him again, he added: “I just hope that Americans get the data they want from scientists and not from politicians. “
Three corporations are in a complex level of Phase 3 clinical trials aiming to recruit 30,000 Americans, some of whom will get the candidate vaccine and some of whom will get a placebo.
Dr. Collins said he was “cautiously optimistic” about having a safe and effective vaccine in place by the end of the year, he added, “but even that is a guess. “
Even as trials progress, big questions arise about who will get a vaccine first and how it will be distributed. Adams told the panel that the administration intends to take into account the rules later Wednesday that would allow state-approved pharmacists to vaccinate those ages 3 and older.
Advertisement